Edwards Lifesciences Corporation is a global leader in heart valve therapies and hemodynamic monitoring. The company's mission is to enhance the quality of life for patients with cardiovascular disease through innovative technologies and solutions. Edwards Lifesciences focuses on research and development to drive advancements in minimally invasive heart valve replacement and repair, as well as critical care monitoring. By collaborating with healthcare professionals and leveraging cutting-edge technology, the company aims to improve patient outcomes and expand access to life-saving treatments worldwide.

EDWARDS LIFESCIENCES CORP

Edwards Lifesciences reported impressive fourth-quarter results, emphasizing its core business in transcatheter aortic valve replacement (TAVR) devices. For the fourth quarter of 2024, the company posted adjusted earnings per share (EPS) of 59 cents, surpassing analyst expectations of 55 cents. Total revenue reached $1.39 billion, a significant 9% increase year-over-year,...

Edwards Lifesciences Reports Strong Q4 Results Driven by TAVR Sales, Shares Surge Over 6% Amid Growth Outlook

Edwards Lifesciences has reported a remarkable fourth quarter, with TAVR sales driving a 9% revenue increase and exceeding earnings expectations. As the company navigates a competitive landscape, can its strategic acquisitions and projected growth sustain this momentum?